Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial.

ABSTRACT:

Background

Peripheral T-cell lymphoma (PTCL) is a heterogeneous disease with dismal outcomes. We conducted an open-label, phase 2 nonrandomised, externally controlled study to evaluate the efficacy and safety of targeted agents plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) (CHOPX) for PTCL in the front-line setting.

Methods

Eligible patients were ≥18 years of age and newly diagnosed PTCL. Patients in the CHOPX group received standard CHOP at Cycle 1. Specific targeted agents were added from Cycle 2, decitabine if TP53 ^mut, azacytidine if TET2/KMT2D ^mut, tucidinostat if CREBBP/EP300 ^mut, and lenalidomide if without mutations above. Patients in the CHOP group received CHOP for 6 cycles. The primar

SUBMITTER: Cai MC 

PROVIDER: S-EPMC11339047 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature